MAPT and early-onset autosomal dominant Alzheimer disease: Dose-related decreases were demonstrated in downstream Alzheimer’s disease biomarkers: tau PET, CSF p-tau and plasma p-tau 181.16 These data demonstrate that removing Aβ ameliorates the downstream tau pathology and cognition.